中国临床康复
中國臨床康複
중국림상강복
CHINESE JOURNAL OF CLINICAL REHABILITATION
2005年
6期
242-244
,共3页
黄晴%吴立军%田代真一%小野寺敏%池岛乔
黃晴%吳立軍%田代真一%小野寺敏%池島喬
황청%오립군%전대진일%소야사민%지도교
水飞蓟素%细胞周期%细胞凋亡
水飛薊素%細胞週期%細胞凋亡
수비계소%세포주기%세포조망
背景:宫颈癌是危害女性身体健康,降低生活质量的疾病之一.利用中药治疗宫颈癌,降低放射治疗、应用抗肿瘤药物治疗副作用对机体伤害已成为医药界的研究热点.在欧洲,水飞蓟素曾广泛用于临床的肝炎治疗.它毒性小,在植物中含量高.因此,一些学者正在研究其抗肿瘤的活性.目的:探讨水飞蓟素对人子宫颈癌细胞的药理作用机制.设计:以体外10%血清正常培养的细胞作为阴性对照的实验对照研究.单位:沈阳药科大学中日医药研究所,昭和药科大学病态科学教研室.材料:人的宫颈癌HeLa细胞为本实验室保存的美国ATCC细胞系.实验于2003-02/07在沈阳药科大学中日医药研究所细胞室完成.方法:噻唑蓝还原法(MTT)分析HeLa细胞的死亡率.采用相差和荧光显微镜观察细胞形态学改变.用流式细胞术分析了细胞周期的变化.主要观察指标:细胞死亡率和细胞周期分化的变化.结果:水飞蓟素诱导的HeLa细胞死亡与培养液中血清含量有关.给予80 μmol/L的水飞蓟素作用,去血清组的细胞死亡率达到85.27%,含5%,10%血清组的死亡率为35.53%,7.71%.细胞的形态学变化表明水飞蓟素诱导的HeLa细胞发生凋亡.流式细胞分析结果显示:水飞蓟素诱导70.04%的细胞发生凋亡,这些凋亡细胞主要来自G0/G1期.结论:水飞蓟素在去血清条件下,诱导处于G0/G1期的HeLa细胞发生凋亡.
揹景:宮頸癌是危害女性身體健康,降低生活質量的疾病之一.利用中藥治療宮頸癌,降低放射治療、應用抗腫瘤藥物治療副作用對機體傷害已成為醫藥界的研究熱點.在歐洲,水飛薊素曾廣汎用于臨床的肝炎治療.它毒性小,在植物中含量高.因此,一些學者正在研究其抗腫瘤的活性.目的:探討水飛薊素對人子宮頸癌細胞的藥理作用機製.設計:以體外10%血清正常培養的細胞作為陰性對照的實驗對照研究.單位:瀋暘藥科大學中日醫藥研究所,昭和藥科大學病態科學教研室.材料:人的宮頸癌HeLa細胞為本實驗室保存的美國ATCC細胞繫.實驗于2003-02/07在瀋暘藥科大學中日醫藥研究所細胞室完成.方法:噻唑藍還原法(MTT)分析HeLa細胞的死亡率.採用相差和熒光顯微鏡觀察細胞形態學改變.用流式細胞術分析瞭細胞週期的變化.主要觀察指標:細胞死亡率和細胞週期分化的變化.結果:水飛薊素誘導的HeLa細胞死亡與培養液中血清含量有關.給予80 μmol/L的水飛薊素作用,去血清組的細胞死亡率達到85.27%,含5%,10%血清組的死亡率為35.53%,7.71%.細胞的形態學變化錶明水飛薊素誘導的HeLa細胞髮生凋亡.流式細胞分析結果顯示:水飛薊素誘導70.04%的細胞髮生凋亡,這些凋亡細胞主要來自G0/G1期.結論:水飛薊素在去血清條件下,誘導處于G0/G1期的HeLa細胞髮生凋亡.
배경:궁경암시위해녀성신체건강,강저생활질량적질병지일.이용중약치료궁경암,강저방사치료、응용항종류약물치료부작용대궤체상해이성위의약계적연구열점.재구주,수비계소증엄범용우림상적간염치료.타독성소,재식물중함량고.인차,일사학자정재연구기항종류적활성.목적:탐토수비계소대인자궁경암세포적약리작용궤제.설계:이체외10%혈청정상배양적세포작위음성대조적실험대조연구.단위:침양약과대학중일의약연구소,소화약과대학병태과학교연실.재료:인적궁경암HeLa세포위본실험실보존적미국ATCC세포계.실험우2003-02/07재침양약과대학중일의약연구소세포실완성.방법:새서람환원법(MTT)분석HeLa세포적사망솔.채용상차화형광현미경관찰세포형태학개변.용류식세포술분석료세포주기적변화.주요관찰지표:세포사망솔화세포주기분화적변화.결과:수비계소유도적HeLa세포사망여배양액중혈청함량유관.급여80 μmol/L적수비계소작용,거혈청조적세포사망솔체도85.27%,함5%,10%혈청조적사망솔위35.53%,7.71%.세포적형태학변화표명수비계소유도적HeLa세포발생조망.류식세포분석결과현시:수비계소유도70.04%적세포발생조망,저사조망세포주요래자G0/G1기.결론:수비계소재거혈청조건하,유도처우G0/G1기적HeLa세포발생조망.
BACKGROUND: Uterine cervix cancer is one of the diseases to damage female health and degrade quality of life. It has been a hot spot to decrease the side effects of radiotherapy and chemotherapy and anti-tumor medicine by using Chinese medicine in medical domain. In Europe, silymarin had been used to treat hepatitis. It had little toxic action and large contents in Chinese herb. Therefore, many researchers are studying its anti-tumor effects now.OBJECTIVE: To study the pharmacological mechanism of silymarin on human cervical cancer cell.DESIGN: The cells cultured in 10% serum medium served as negative control group in vitro.MATERIALS: The experiment was finished in the China-Japan Research Institute of Medical and Pharmaceutical Sciences in Shenyang Pharmaceutical University; Department of Pathological Science of Showa Medical UniversityMATERIASLS: Human cervical cancer cell (HeLa) is the preservative cell line of American ATCC in the Lab. The experiment was completed in the Cell Lab of China-Japan Research Institute of Medical and Pharmaceutical Sciences in Shenyang Pharmaceutical University from Feburary 2003 to July 2003.METHODS: HeLa cell death ratio was measured by methyl thiazol tetrazolium(MTT) assay. Cellular morphologic changes were observed by phase-contrast and fluorescence microscopy. Cell cycle distribution was analyzed by flow cytometry.MAIN OUTCOME MEASURES: The changes of cell death ratio and cell cycle distribution.RESULTS: Silymarin-induced HeLa cell death was relevant to the content of serum in medium. At the does of 80 μmol /L silymarin, the cell death ratio in serum-free group reached 85.27%. The cell death ratio in 5% and 10%serum groups was 35.53% and 7.71% respectively. Morphological changes of HeLa cells demonstrated that silymarin induced HeLa cell death through apoptotic pathway at lower concentration in serum-free condition. Flow cytometry analysis showed that silymarin induced 70. 04% cells death, most of which were in G0/G1 phase.CONCLUSION: Silymarin mainly induce G0/G1 phase HeLa cell death through apoptotic pathway in serum-free medium.